Jasper Therapeutics Inc

NASDAQ:JSPR USA Biotechnology
Market Cap
$34.98 Million
Market Cap Rank
#24041 Global
#8344 in USA
Share Price
$1.25
Change (1 day)
+2.46%
52-Week Range
$1.14 - $6.82
All Time High
$164.20
About

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercializ… Read more

Jasper Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2020: 53.37%

Jasper Therapeutics Inc (JSPR) has an Asset Resilience Ratio of 53.37% as of March 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$54.33 Million
Cash + Short-term Investments
Total Assets
$101.79 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Jasper Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Jasper Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $54.33 Million 53.37%
Total Liquid Assets $54.33 Million 53.37%

Asset Resilience Insights

  • Very High Liquidity: Jasper Therapeutics Inc maintains exceptional liquid asset reserves at 53.37% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jasper Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Jasper Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Jasper Therapeutics Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Jasper Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points